7-氯-6-氟-1-异丙基-4-氧代-1,4-二氢喹啉-3-羧酸 | 70032-19-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 7-氯-6-氟-1-异丙基-4-氧代-1,4-二氢喹啉-3-羧酸
• 英文名称: 7-chloro-6-fluoro-1-isopropyl-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
• 英文别名: 7-Chloro-6-fluoro-4-oxo-1-propan-2-ylquinoline-3-carboxylic acid
• CAS: 70032-19-8
• 化学式: C₁₃H₁₁ClFNO₃
• 分子量: 283.687
• InChiKey: GBRHQMDODCICAI-UHFFFAOYSA-N

物化性质

• 沸点：
  438.2±45.0 °C(Predicted)
• 密度：
  1.450±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  57.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  7-氯-6-氟-1-异丙基-4-氧代-1,4-二氢喹啉-3-羧酸 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 反应 20.0h， 生成 7-chloro-6-{2-[2-(2-cyanoethoxy)-ethoxy]ethylamino}-1-isopropyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
  参考文献：
  名称：

  新型抗菌15元环大分子克隆的合成，活性和药代动力学

  摘要：

  据报道，一类新的大环内酯类抗生素-大环酮类化合物-其衍生自阿奇霉素，其接头中含有一个或多个氧原子，并且具有游离或酯化的喹诺酮3-羧基基团，具有合成，抗菌活性和药代动力学特性。选定的化合物对关键的红霉素抗性呼吸道病原体表现出优异的抗菌作用。但是，大多数化合物缺乏良好的生物利用度。异丙酯，化合物35和带有加长接头29的大酮衍生物在大鼠中显示出最佳的口服生物利用度，同时具有出色的整体微生物学特征，可解决链球菌中的诱导型和组成型MLSb以及外排介导的大环内酯耐药性，而化合物29 对葡萄球菌更有效。

  DOI：

  10.1016/j.ejmech.2011.05.002
• 作为产物：
  描述：

  2-(2,4-二氯-5-氟苯甲酰基)-3-乙氧基丙烯酸乙酯 在 氢氧化钾 、 sodium hydride 作用下， 以 1,4-二氧六环 、 乙醇 、 水 为溶剂， 反应 4.5h， 生成 7-氯-6-氟-1-异丙基-4-氧代-1,4-二氢喹啉-3-羧酸
  参考文献：
  名称：

  Fluoronaphthyridines and quinolones as antibacterial agents. 1. Synthesis and structure-activity relationship of new 1-substituted derivatives

  摘要：

  A series of novel 7-piperazinyl-1-substituted-6-fluoroquinolones and naphthyridines have been prepared and their antibacterial activities evaluated. These derivatives are characterized by having alkyl, alkenyl, arylalkyl, cycloalkyl, and cycloalkenyl groups at the 1-position. As a result of this study, derivatives 7 and 26, which are substituted with tert-butyl groups at N-1, were found to possess excellent in vitro and in vivo potency, particularly against Staphylococcus aureus, comparable to that of norfloxacin or ciprofloxacin. Structure-activity relationships of N-1 substituted alkyls and cycloalkyls are also discussed.

  DOI：

  10.1021/jm00123a005

文献信息

• Ether linked macrolides useful for the treatment of microbial infections
  申请人：Alihodzic Sulejman

  公开号：US20060258600A1

  公开（公告）日：2006-11-16

  The present invention relates to 14- or 15-membered macrolides substituted at the 4″ position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infections in a human or animal body.

  本发明涉及在式(I)的4″位置被取代的14-或15-元大环内酯及其药学上可接受的衍生物，以及它们的制备过程和在人体或动物体内治疗或预防全身或局部微生物感染中的用途。
• An operational transformation of 3-carboxy-4-quinolones into 3-nitro-4-quinolones via ipso-nitration using polysaccharide supported copper nanoparticles: synthesis of 3-tetrazolyl bioisosteres of 3-carboxy-4-quinolones as antibacterial agents
  作者：Chandra S. Azad、Anudeep K. Narula

  DOI：10.1039/c5ra26909a

  日期：——

  Chitosan supported Cu nano-particles have been synthesized, and utilized for the synthesis of 3-nitro-4-quinolones from 3-carboxy-4-quinolones via ipso nitration. The synthesized 3-nitro derivatives of 4-quinolones were successfully converted into their 3-tetrazolyl bioisosteres which showed increased antibacterial activity as compared to the standard ciprofloxacin.

  壳聚糖负载的Cu纳米粒子已经合成，并用于通过ipso硝化反应从3-羧基-4-喹诺酮类化合物合成3-硝基-4-喹诺酮类化合物。与标准环丙沙星相比，4-喹诺酮的合成3-硝基衍生物已成功转化为3-四唑基生物甾醇，其抗菌活性增强。
• Developing ciprofloxacin analogues against plant DNA gyrase: a novel herbicide mode of action
  作者：Michael D. Wallace、Nidda F. Waraich、Aleksandra W. Debowski、Maxime G. Corral、Anthony Maxwell、Joshua S. Mylne、Keith A. Stubbs

  DOI：10.1039/c7cc09518j

  日期：——

  The development of ciprofloxacin analogues against plant DNA gyrase, a novel herbicidal target, with increased herbicidal activity and diminished antibacterial activity is described.

  描述了对植物DNA旋转酶的环丙沙星类似物的开发，这是一种新的除草靶标，具有增强的除草活性和减弱的抗菌活性。
• [EN] ESTER LINKED MACROLIDES USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS<br/>[FR] MACROLIDES A LIAISON ESTER UTILES POUR LE TRAITEMENT D'INFECTION MICROBIENNES
  申请人：PLIVA ISTRAZIVACKI INST D O O

  公开号：WO2005108412A1

  公开（公告）日：2005-11-17

  The present invention relates to 14- or 15-membered macrolides substituted at the 4” position of formula (I) and pharmaceutically acceptable derivatives thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical microbial infoections in a human or animal body.

  本发明涉及在式（I）的4”位置被取代的14-或15-环大环内酯及其药学上可接受的衍生物，以及它们的制备方法和在人体或动物体内治疗或预防全身或局部微生物感染中的用途。
• [EN] MONOCARBOXYLATE TRANSPORT MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE TRANSPORT DES MONOCARBOXYLATES ET LEURS UTILISATIONS
  申请人：NIROGYONE THERAPEUTICS INC

  公开号：WO2016081464A1

  公开（公告）日：2016-05-26

  The invention generally relates to the field of monocarboxylate transport modulators, e.g., monocarboxylate transport inhibitors, and more particularly to new substituted-quinolone compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in treating, modulating, forestalling and/or reducing physiological conditions associated with monocarboxylate transport activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, obesity, diabetes, cardiovascular diseases, tissue and organ transplant rejection, and malaria.

  这项发明通常涉及单羧酸转运调节剂领域，例如单羧酸转运抑制剂，更具体地涉及新的取代喹啉酮化合物，这些化合物的合成和使用以及它们的药物组合物，例如在治疗、调节、预防和/或减少与单羧酸转运活性相关的生理状况，如治疗癌症和其他肿瘤性疾病、炎症性疾病、异常组织生长和纤维化障碍包括心肌病、肥胖症、糖尿病、心血管疾病、组织和器官移植排斥反应以及疟疾。